Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 MARKETS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
• 4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
• 4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
• 4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
• 4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Changing lifestyle and dietary habits
    • 5.2.1.2 Steady development and approvals of drugs
    • 5.2.1.3 Favorable reimbursement and insurance policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Off-label use of drugs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Shifting focus on new drug modalities
    • 5.2.3.2 Rapidly expanding market in developing countries
    • 5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Non-adherence to treatments
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Hybridoma technology
    • 5.3.1.2 Recombinant DNA technology
    • 5.3.1.3 Antibody engineering
  • 5.3.2 ADJACENT TECHNOLOGIES
    • 5.3.2.1 Tissue engineering (scaffold technology)
    • 5.3.2.2 Artificial intelligence
    • 5.3.2.3 Optogenetic technology
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
  • 5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
  • 5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 PATENT ANALYSIS
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY LANDSCAPE
    • 5.10.1.1 US
    • 5.10.1.2 Europe
    • 5.10.1.3 Emerging economies
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 INVESTMENT/FUNDING ACTIVITY
• 5.15 PIPELINE ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
  • 5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
  • 5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT
• 5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET

6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 EYLEA & EYLEA HD
  • 6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS TO SPEED UP GROWTH
• 6.3 LUCENTIS
  • 6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL THICKNESS TO FAVOR GROWTH
• 6.4 VABYSMO
  • 6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES TO SUSTAIN GROWTH
• 6.5 SYFOVRE
  • 6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED MACULAR DEGENERATION TO BOOST MARKET
• 6.6 OTHER PRODUCTS

7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE

• 7.1 INTRODUCTION
• 7.2 AFLIBERCEPT
  • 7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS TO EXPEDITE GROWTH
• 7.3 FARICIMAB
  • 7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH STUDIES TO AUGMENT GROWTH
• 7.4 RANIBIZUMAB
  • 7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
• 7.5 PEGCETACOPLAN
  • 7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO CONTRIBUTE TO GROWTH
• 7.6 OTHER MOLECULES

8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE

• 8.1 INTRODUCTION
• 8.2 BIOLOGICS
  • 8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES TO SUPPORT GROWTH
• 8.3 BIOSIMILARS
  • 8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH

9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD

• 9.1 INTRODUCTION
• 9.2 WET AMD
  • 9.2.1 GROWING GERIATRIC POPULATION TO FACILITATE GROWTH
• 9.3 DRY AMD
  • 9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH

10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
• 10.4 SPECIALTY CENTERS
  • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising investment in healthcare research & development to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable government initiatives to aid market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth
  • 11.3.3 UK
    • 11.3.3.1 Ongoing technological advancements to promote growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth
  • 11.3.5 ITALY
    • 11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing number of collaborative projects to favor market growth
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Strategic drug approvals to support market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to encourage growth
  • 11.4.4 INDIA
    • 11.4.4.1 Regulatory reforms and aging population to boost market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Supportive regulatory environment to boost market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increasing rate of visual impairment to sustain growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
    • 11.6.2.3 Other GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
• 12.3 REVENUE ANALYSIS, 2021-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Molecule footprint
    • 12.5.5.3 Approval footprint
    • 12.5.5.4 Type of AMD footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7.1 COMPANY VALUATION
  • 12.7.2 FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 F. HOFFMANN-LA ROCHE LTD
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 REGENERON PHARMACEUTICALS INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 NOVARTIS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 BAYER AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches & approvals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 APELLIS PHARMACEUTICALS
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.2.1 Weaknesses and competitive threats
  • 13.1.6 ASTELLAS PHARMA INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 STADA ARZNEIMITTEL AG
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 BIOGEN
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & approvals
  • 13.1.9 FORMYCON AG
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches & approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 COHERUS BIOSCIENCES
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Products launches & approvals
      • 13.1.10.3.2 Other developments
  • 13.1.11 BIOCON
    • 13.1.11.1 Business overview
    • 13.1.11.2 Product offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches & approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 OUTLOOK THERAPEUTICS, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches & approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches & approvals
      • 13.1.13.3.2 Deals
  • 13.1.14 INTAS PHARMACEUTICALS LTD.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 SANDOZ GROUP AG
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches & approvals
      • 13.1.15.3.2 Deals
      • 13.1.15.3.3 Expansions
  • 13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 OCULAR THERAPEUTIX, INC.
  • 13.2.2 OPTHEA LIMITED
  • 13.2.3 KODIAK SCIENCES INC.
  • 13.2.4 BIO-THERA
  • 13.2.5 AMGEN INC.
  • 13.2.6 ALVOTECH
  • 13.2.7 STEALTH BIOTHERAPEUTICS INC.
  • 13.2.8 ALTEOGEN INC.
  • 13.2.9 OCUMENSION THERAPEUTICS
  • 13.2.10 INNOVENT
  • 13.2.11 SHANGHAI HENLIUS BIOTECH, INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 INCLUSIONS AND EXCLUSIONS
• TABLE 2 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
• TABLE 3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE), 2021-2023 (USD)
• TABLE 4 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER, 2021-2023 (USD)
• TABLE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 6 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• TABLE 7 INNOVATIONS AND PATENT REGISTRATIONS, 2019-2023
• TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
• TABLE 15 BUYING CRITERIA FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER
• TABLE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS IN CLINICAL PIPELINE, PHASE 3
• TABLE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 18 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2023-2029 (MILLION UNITS)
• TABLE 19 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 20 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 21 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 22 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 25 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 27 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 28 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 29 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 30 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 31 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 32 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 33 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
• TABLE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 35 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 36 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 37 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
• TABLE 39 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 41 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 42 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 43 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 46 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 47 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 48 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 49 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 50 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 53 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 54 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 55 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 56 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 58 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 60 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 61 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 62 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
• TABLE 63 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 65 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 67 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
• TABLE 68 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 69 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
• TABLE 70 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 73 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 74 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
• TABLE 75 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 76 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
• TABLE 77 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 78 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 79 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 80 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 81 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
• TABLE 82 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 83 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 84 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 85 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 86 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 87 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 88 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 89 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 90 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 91 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 92 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 93 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 94 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 95 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 96 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 97 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 98 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 99 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 100 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 101 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 102 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 103 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 104 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 105 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 106 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 107 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 108 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 109 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 110 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 111 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 112 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 113 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 114 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 115 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 116 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 117 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 118 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
• TABLE 119 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 120 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 121 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 122 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 123 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 124 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 125 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 126 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 127 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 128 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 129 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 130 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 131 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 132 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 133 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 134 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 135 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 136 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 137 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 138 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 140 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 141 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 142 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 143 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 144 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 145 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 146 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 147 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 148 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 149 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN NORTH AMERICA
• TABLE 150 US HEALTHCARE SPENDING, 2020-2022 (USD MILLION)
• TABLE 151 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 152 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 153 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 154 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 155 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 156 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 157 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 158 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 159 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 160 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 161 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 162 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 163 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 164 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 165 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 166 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 167 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN EUROPE
• TABLE 168 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 169 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 170 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 171 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 172 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 173 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 174 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 175 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 176 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 177 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 178 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 179 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 180 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 181 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 182 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 183 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 184 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 185 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 186 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 187 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 188 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 189 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 190 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 191 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 192 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 193 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 194 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 195 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 196 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 197 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 198 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 199 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 200 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 201 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 202 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 203 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 204 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 205 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 206 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 207 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 208 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 209 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN ASIA PACIFIC
• TABLE 210 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 211 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 212 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 213 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 214 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 215 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 216 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 217 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 218 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 219 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 220 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 221 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 222 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 223 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 224 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 225 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 226 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 227 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 228 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 229 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 230 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 231 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 232 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 233 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 234 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 235 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 236 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 237 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 238 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 239 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 240 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 241 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 242 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 243 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 244 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 245 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 246 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN LATIN AMERICA
• TABLE 247 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 248 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 249 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 250 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 251 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 252 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 253 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 254 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 255 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 256 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 257 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 258 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 259 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 260 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 261 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 262 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 263 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 264 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 265 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 266 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 267 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 268 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN MIDDLE EAST
• TABLE 269 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 270 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 271 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 272 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 273 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 274 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 275 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 276 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 277 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 278 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 279 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 280 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 281 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 282 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 283 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 284 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 285 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 286 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 287 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 288 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 289 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 290 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 291 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 292 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 293 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 294 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 295 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 296 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 297 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
• TABLE 298 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
• TABLE 299 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 300 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN AFRICA
• TABLE 301 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
• TABLE 302 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEGREE OF COMPETITION
• TABLE 303 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: MOLECULE FOOTPRINT
• TABLE 304 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: APPROVAL TYPE FOOTPRINT
• TABLE 305 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: TYPE OF AMD FOOTPRINT
• TABLE 306 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REGION FOOTPRINT
• TABLE 307 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 308 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 309 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 310 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEALS, JANUARY 2021- AUGUST 2024
• TABLE 311 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
• TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
• TABLE 313 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
• TABLE 314 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 315 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
• TABLE 316 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
• TABLE 317 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 318 NOVARTIS AG: COMPANY OVERVIEW
• TABLE 319 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 320 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 321 NOVARTIS AG: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 322 BAYER AG: COMPANY OVERVIEW
• TABLE 323 BAYER AG: PRODUCTS OFFERED
• TABLE 324 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 325 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 326 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 327 APELLIS PHARMACEUTICALS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 328 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 329 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
• TABLE 330 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
• TABLE 331 ASTELLAS PHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 332 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 333 STADA ARZNEIMITTEL AG: COMPANY OVERVIEW
• TABLE 334 STADA ARZNEIMITTEL AG: PRODUCTS OFFERED
• TABLE 335 STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 336 STADA ARZNEIMITTEL AG: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 337 BIOGEN: COMPANY OVERVIEW
• TABLE 338 BIOGEN: PRODUCTS OFFERED
• TABLE 339 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 340 FORMYCON AG: COMPANY OVERVIEW
• TABLE 341 FORMYCON AG: PRODUCTS OFFERED
• TABLE 342 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 343 FORMYCON AG: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 344 COHERUS BIOSCIENCES: COMPANY OVERVIEW
• TABLE 345 COHERUS BIOSCIENCES: PRODUCTS OFFERED
• TABLE 346 COHERUS BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 347 COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 348 BIOCON: COMPANY OVERVIEW
• TABLE 349 BIOCON: PRODUCTS OFFERED
• TABLE 350 BIOCON: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 351 BIOCON: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 352 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
• TABLE 353 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 355 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 356 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
• TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 360 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
• TABLE 361 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
• TABLE 362 SANDOZ GROUP AG: COMPANY OVERVIEW
• TABLE 363 SANDOZ GROUP AG: PRODUCTS OFFERED
• TABLE 364 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 365 SANDOZ GROUP AG: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 366 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2021-AUGUST 2024
• TABLE 367 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
• TABLE 368 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
• TABLE 369 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
• TABLE 370 OPTHEA LIMITED: COMPANY OVERVIEW
• TABLE 371 KODIAK SCIENCES INC.: COMPANY OVERVIEW
• TABLE 372 BIO-THERA: COMPANY OVERVIEW
• TABLE 373 AMGEN INC.: COMPANY OVERVIEW
• TABLE 374 ALVOTECH: COMPANY OVERVIEW
• TABLE 375 STEALTH BIOTHERAPEUTICS INC.: COMPANY OVERVIEW
• TABLE 376 ALTEOGEN INC.: COMPANY OVERVIEW
• TABLE 377 OCUMENSION THERAPEUTICS: COMPANY OVERVIEW
• TABLE 378 INNOVENT: COMPANY OVERVIEW
• TABLE 379 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION
• FIGURE 2 RESEARCH DESIGN
• FIGURE 3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
• FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
• FIGURE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REVENUE SHARE ANALYSIS, 2023
• FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: COMPANY REVENUE SHARE ANALYSIS, 2023
• FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
• FIGURE 8 BOTTOM-UP APPROACH
• FIGURE 9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: CAGR PROJECTIONS, 2024-2029
• FIGURE 10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
• FIGURE 11 DATA TRIANGULATION
• FIGURE 12 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF APPROVAL, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2024-2029
• FIGURE 18 GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLES TO DRIVE MARKET
• FIGURE 19 BIOLOGICS SEGMENT AND US DOMINATED NORTH AMERICAN MARKET IN 2023
• FIGURE 20 WET AMD SEGMENT TO LEAD MARKET BY 2029
• FIGURE 21 HOSPITALS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 22 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 23 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 REVENUE SHIFT & NEW POCKETS FOR AGE-RELATED MACULAR DEGENERATION THERAPY PROVIDERS
• FIGURE 25 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2021-2023 (USD)
• FIGURE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 27 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 28 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 29 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PATENT ANALYSIS, 2014-2024
• FIGURE 30 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS
• FIGURE 32 KEY BUYING CRITERIA, BY END USER
• FIGURE 33 IMPACT OF ARTIFICIAL INTELLIGENCE ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
• FIGURE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
• FIGURE 35 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
• FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
• FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 38 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 39 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY FOOTPRINT
• FIGURE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 42 EV/EBITDA OF KEY VENDORS
• FIGURE 43 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
• FIGURE 45 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2023)
• FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023)
• FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2023)
• FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023)
• FIGURE 49 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2023)
• FIGURE 50 BIOGEN: COMPANY SNAPSHOT (2023)
• FIGURE 51 FORMYCON AG: COMPANY SNAPSHOT (2023)
• FIGURE 52 BIOCON: COMPANY SNAPSHOT (2023)
• FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 54 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)